
Hadrien has been in charge of different positions at Kurma (analyst, associate and now as principal). He has participated in a dozen investments of the Kurma Biofund II and III funds. Hadrien has actively contributed in particular to the creation of several portfolio companies such as Dynacure, Imcheck Therapeutics, Flamingo Therapeutics, Ermium Therapeutics and Corlieve Therapeutics. Hadrien holds a PharmD from the Faculty of Pharmacy, Lille, and a Master in Entrepreneurship from the ESSEC Business School.